LONDON (Alliance News) - Quantum Pharma PLC on Wednesday said its Biodose Connect telemedicine technology has completed validation testing in the UK and has been given Class 1 medical device status.
The validation, from the Medicines and Healthcare products Regulatory Agency, means Quantum can now commence its commercialisation strategy for the product.
Quantum said the device is now ready for use in live patient settings, allowing patients, carers, doctors or pharmacists to be alerted by remote monitoring when medicines are not taken as prescribed.
"We are delighted that our Biodose Connect device now has Class I medical device status and we can start to commercialise it. It is an exciting product that we believe will provide a huge benefit to the NHS, social care providers and pharmaceutical companies, not only by reducing the burden created by medication non-adherence, but also in allowing patients to be treated at home," said Quantum Chief Executive Andrew Scaife.
Quantum shares were down 1.4% near the open on Wednesday at 72.45 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
